IONIS PHARMACEUTICALS INC (IONS)

Ionis Publishes 2023 Corporate Responsibility Report

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report...

Ionis to hold first quarter 2024 financial results webcast

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to...

Ionis to present at upcoming investor conferences

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor...

Ionis to hold olezarsen Phase 3 data webcast

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to...

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present positive Phase 3 Balance results in patients with familial...

Ionis Pharmaceuticals Enters Oversold Territory (IONS)

Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense...

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis as executive vice president, chief global product...

Ionis to present at upcoming investor conferences

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor...

Bullish Two Hundred Day Moving Average Cross - IONS

Ionis Pharmaceuticals GAAP EPS of -$0.06 beats by $0.80, revenue of $325M beats by $154.1M (NASDAQ:IONS)

Ionis Pharmaceuticals reported strong financial results for Q4 2023, with revenues exceeding expectations and a significant increase compared to the...

Ionis reports fourth quarter and full year 2023 financial results

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the fourth quarter and full year ended...

First Week of IONS October 18th Options Trading

Ionis receives FDA orphan drug status for familial chylomicronemia drug (NASDAQ:IONS)

Ionis Pharmaceuticals receives orphan drug status from FDA for experimental drug, olezarsen, in the treatment of familial chylomicronemia syndrome (FCS).

Ionis Pharmaceuticals Larger Than S&P 500 Component Invesco

Ionis-AstraZeneca amyloid cardiomyopathy candidate gets FDA fast track designation

The FDA grants fast track status to Ionis Pharmaceuticals and AstraZeneca for investigation therapy for amyloid cardiomyopathy in adults.

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...

Ionis to hold fourth quarter and full year 2023 financial results webcast

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern...

January 2025 Options Now Available For Ionis Pharmaceuticals

Ionis angioedema drug shows positive results in Phase 3 trial (NASDAQ:IONS)

Ionis Pharmaceuticals announces positive Phase 3 trial results for donidalorsen, a drug candidate for hereditary angioedema, with plans for regulatory...

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2023 achievements and previewed a number of important...

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Ionis shares climb 5% after BofA upgrades stock to buy (NASDAQ:IONS)

Shares of Ionis Pharmaceuticals (IONS) rose 5% after BofA upgraded the stock to buy and raised its price target to $62 from $52. Read more here.

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies

These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024.

FDA approves AstraZeneca, Ionis drug for ATTRv-PN (IONS0

The FDA has approved AstraZeneca (AZN) and Ionis Pharmaceuticals' (IONS) drug Wainua for the treatment of ATTRv-PN. Read more here.